绝经后泌乳素分泌型微腺瘤女性高泌乳素血症的治疗：共识 - Suppr

The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.

作者信息

Faje Alexander T, Klibanski Anne

机构信息

BUL 457, Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.

出版信息

Endocrine. 2015 Feb;48(1):79-82. doi: 10.1007/s12020-014-0308-9. Epub 2014 Jun 3.

DOI:10.1007/s12020-014-0308-9

PMID:24888765

Abstract

摘要

相似文献

The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.

Endocrine. 2015 Feb;48(1):79-82. doi: 10.1007/s12020-014-0308-9. Epub 2014 Jun 3.

Treatment of hyperprolactinemia in post-menopausal women: pros.

Endocrine. 2015 Feb;48(1):76-8. doi: 10.1007/s12020-014-0377-9. Epub 2014 Aug 12.

Hyperprolactinemic disorders.

Clin Obstet Gynecol. 1990 Sep;33(3):622-39. doi: 10.1097/00003081-199009000-00027.

[Hyperprolactinemia unrelated to prolactinoma].

Wiad Lek. 2014;67(2 Pt 1):101-11.

Prolactinomas.

Endocrinol Metab Clin North Am. 2015 Mar;44(1):71-8. doi: 10.1016/j.ecl.2014.11.003. Epub 2014 Nov 6.

[Hyperprolactinemia in the postmenopause: versions and contraversions].

Ter Arkh. 2021 Oct 15;93(10):1234-1239. doi: 10.26442/00403660.2021.10.201073.

Hyperprolactinemia after menopause: Diagnosis and management.

Maturitas. 2021 Sep;151:36-40. doi: 10.1016/j.maturitas.2021.06.014. Epub 2021 Jul 3.

Hyperprolactinemia and prolactinoma.

Handb Clin Neurol. 2014;124:185-95. doi: 10.1016/B978-0-444-59602-4.00013-7.

Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia.

Gynecol Endocrinol. 2017 Feb;33(2):148-151. doi: 10.1080/09513590.2016.1222363. Epub 2016 Nov 12.

[Hyperprolactinemia and prolactinomas].

Ned Tijdschr Geneeskd. 1991 Nov 23;135(47):2210-3.

引用本文的文献

Impact of medical therapy for hormone-secreting Pituitary tumors on bone.

Pituitary. 2024 Dec;27(6):860-873. doi: 10.1007/s11102-024-01421-z. Epub 2024 Jul 5.

Metabolic effects of prolactin.

Front Endocrinol (Lausanne). 2022 Sep 27;13:1015520. doi: 10.3389/fendo.2022.1015520. eCollection 2022.

Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.

Sci Rep. 2021 Mar 4;11(1):5122. doi: 10.1038/s41598-021-84606-x.

Update on vertebral fractures in pituitary diseases: from research to clinical practice.

Hormones (Athens). 2021 Sep;20(3):423-437. doi: 10.1007/s42000-021-00275-5. Epub 2021 Feb 19.

Postmenopausal Hyperandrogenism: Evaluation and Treatment Strategies.

Endocrinol Metab Clin North Am. 2021 Mar;50(1):97-111. doi: 10.1016/j.ecl.2020.12.002. Epub 2021 Jan 11.

Prolactinomas and menopause: any changes in management?

Pituitary. 2020 Feb;23(1):58-64. doi: 10.1007/s11102-019-00998-0.

Management of prolactinoma: a survey of endocrinologists in China.

Endocr Connect. 2018 Oct 1;7(10):1013-1019. doi: 10.1530/EC-18-0250.

[Prolactin-secreting microadenoma in menopausal women].

Pan Afr Med J. 2017 Jul 5;27:177. doi: 10.11604/pamj.2017.27.177.11677. eCollection 2017.

Management of prolactinomas: a survey of physicians from the Middle East and North Africa.

Pituitary. 2017 Apr;20(2):231-240. doi: 10.1007/s11102-016-0767-5.

Prolactinomas: evolution after menopause.

Arch Endocrinol Metab. 2016 Feb;60(1):42-6. doi: 10.1590/2359-3997000000138.

本文引用的文献

Prolactin actions.

J Mol Endocrinol. 2013 Dec 19;52(1):R95-106. doi: 10.1530/JME-13-0220. Print 2014 Feb.

Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.

Eur J Endocrinol. 2013 Aug 28;169(3):359-66. doi: 10.1530/EJE-13-0231. Print 2013 Sep.

A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development.

Cancer Res. 2013 Aug 1;73(15):4810-9. doi: 10.1158/0008-5472.CAN-13-0665. Epub 2013 Jun 19.

Effects of prolactin on platelet activation and blood clotting.

Scand J Clin Lab Invest. 2013 Apr;73(3):221-8. doi: 10.3109/00365513.2013.765963.

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.

Clin Endocrinol (Oxf). 2013 Dec;79(6):845-52. doi: 10.1111/cen.12204. Epub 2013 Apr 22.

Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.

Mol Cancer Ther. 2013 Mar;12(3):295-305. doi: 10.1158/1535-7163.MCT-12-0886. Epub 2012 Dec 27.

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?

Clin Endocrinol (Oxf). 2013 Aug;79(2):217-23. doi: 10.1111/cen.12124. Epub 2013 May 6.

Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas.

Pituitary. 2013 Dec;16(4):523-7. doi: 10.1007/s11102-012-0450-4.

Prolactin secretion in healthy adults is determined by gender, age and body mass index.

PLoS One. 2012;7(2):e31305. doi: 10.1371/journal.pone.0031305. Epub 2012 Feb 17.

Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.

Drug Saf. 2012 Feb 1;35(2):159-71. doi: 10.2165/11594940-000000000-00000.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.

Endocrine. 2015 Feb;48(1):79-82. doi: 10.1007/s12020-014-0308-9. Epub 2014 Jun 3.

Treatment of hyperprolactinemia in post-menopausal women: pros.

Endocrine. 2015 Feb;48(1):76-8. doi: 10.1007/s12020-014-0377-9. Epub 2014 Aug 12.

Hyperprolactinemic disorders.

Clin Obstet Gynecol. 1990 Sep;33(3):622-39. doi: 10.1097/00003081-199009000-00027.

[Hyperprolactinemia unrelated to prolactinoma].

Wiad Lek. 2014;67(2 Pt 1):101-11.

Prolactinomas.

Endocrinol Metab Clin North Am. 2015 Mar;44(1):71-8. doi: 10.1016/j.ecl.2014.11.003. Epub 2014 Nov 6.

[Hyperprolactinemia in the postmenopause: versions and contraversions].

Ter Arkh. 2021 Oct 15;93(10):1234-1239. doi: 10.26442/00403660.2021.10.201073.

Hyperprolactinemia after menopause: Diagnosis and management.

Maturitas. 2021 Sep;151:36-40. doi: 10.1016/j.maturitas.2021.06.014. Epub 2021 Jul 3.

Hyperprolactinemia and prolactinoma.

Handb Clin Neurol. 2014;124:185-95. doi: 10.1016/B978-0-444-59602-4.00013-7.

Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia.

Gynecol Endocrinol. 2017 Feb;33(2):148-151. doi: 10.1080/09513590.2016.1222363. Epub 2016 Nov 12.

[Hyperprolactinemia and prolactinomas].

Ned Tijdschr Geneeskd. 1991 Nov 23;135(47):2210-3.

引用本文的文献

Impact of medical therapy for hormone-secreting Pituitary tumors on bone.

Pituitary. 2024 Dec;27(6):860-873. doi: 10.1007/s11102-024-01421-z. Epub 2024 Jul 5.

Metabolic effects of prolactin.

Front Endocrinol (Lausanne). 2022 Sep 27;13:1015520. doi: 10.3389/fendo.2022.1015520. eCollection 2022.

Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.

Sci Rep. 2021 Mar 4;11(1):5122. doi: 10.1038/s41598-021-84606-x.

Update on vertebral fractures in pituitary diseases: from research to clinical practice.

Hormones (Athens). 2021 Sep;20(3):423-437. doi: 10.1007/s42000-021-00275-5. Epub 2021 Feb 19.

Postmenopausal Hyperandrogenism: Evaluation and Treatment Strategies.

Endocrinol Metab Clin North Am. 2021 Mar;50(1):97-111. doi: 10.1016/j.ecl.2020.12.002. Epub 2021 Jan 11.

Prolactinomas and menopause: any changes in management?

Pituitary. 2020 Feb;23(1):58-64. doi: 10.1007/s11102-019-00998-0.

Management of prolactinoma: a survey of endocrinologists in China.

Endocr Connect. 2018 Oct 1;7(10):1013-1019. doi: 10.1530/EC-18-0250.

[Prolactin-secreting microadenoma in menopausal women].

Pan Afr Med J. 2017 Jul 5;27:177. doi: 10.11604/pamj.2017.27.177.11677. eCollection 2017.

Management of prolactinomas: a survey of physicians from the Middle East and North Africa.

Pituitary. 2017 Apr;20(2):231-240. doi: 10.1007/s11102-016-0767-5.

Prolactinomas: evolution after menopause.

Arch Endocrinol Metab. 2016 Feb;60(1):42-6. doi: 10.1590/2359-3997000000138.

本文引用的文献

Prolactin actions.

J Mol Endocrinol. 2013 Dec 19;52(1):R95-106. doi: 10.1530/JME-13-0220. Print 2014 Feb.

Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.

Eur J Endocrinol. 2013 Aug 28;169(3):359-66. doi: 10.1530/EJE-13-0231. Print 2013 Sep.

A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development.

Cancer Res. 2013 Aug 1;73(15):4810-9. doi: 10.1158/0008-5472.CAN-13-0665. Epub 2013 Jun 19.

Effects of prolactin on platelet activation and blood clotting.

Scand J Clin Lab Invest. 2013 Apr;73(3):221-8. doi: 10.3109/00365513.2013.765963.

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.

Clin Endocrinol (Oxf). 2013 Dec;79(6):845-52. doi: 10.1111/cen.12204. Epub 2013 Apr 22.

Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.

Mol Cancer Ther. 2013 Mar;12(3):295-305. doi: 10.1158/1535-7163.MCT-12-0886. Epub 2012 Dec 27.

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?

Clin Endocrinol (Oxf). 2013 Aug;79(2):217-23. doi: 10.1111/cen.12124. Epub 2013 May 6.

Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas.

Pituitary. 2013 Dec;16(4):523-7. doi: 10.1007/s11102-012-0450-4.

Prolactin secretion in healthy adults is determined by gender, age and body mass index.

PLoS One. 2012;7(2):e31305. doi: 10.1371/journal.pone.0031305. Epub 2012 Feb 17.

Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.

Drug Saf. 2012 Feb 1;35(2):159-71. doi: 10.2165/11594940-000000000-00000.

The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献